Abstract
Cholangiocarcinoma (CCA) is a heterogeneous group of dysplastic disorders affecting the biliary epithelium. It is the second most common primary liver tumor which accounts for around 3% of all gastrointestinal cancers. CCA is very deadly due to its aggressiveness, late diagnosis and high chemoresistance. The incidence is increasing worldwide and the therapeutic options are very limited. Radiotherapy, chemotherapy, surgery and/or liver transplantation may be indicated in patients who meet certain criteria, but chances of success are low. There is therefore increasing interest in understanding the molecular mechanisms involved in the pathogenesis of this cancer type and in identifying new targets for therapy. Current strategies are based on targeting key signaling pathways involved in proliferation, survival, apoptosis and migration. In this review, the most relevant molecular mechanisms involved in the pathogenesis of CCA are discussed and the main preclinical and clinical studies are highlighted. Moreover, future directions in basic and clinical research are indicated.
Keywords: Biliary epithelium, cholangiocarcinoma, cancer, pathogenesis, stroma, molecular mechanisms, therapy.
Graphical Abstract
Current Drug Targets
Title:Molecular Mechanisms of Cholangiocarcinogenesis: New Potential Targets for Therapy
Volume: 18 Issue: 8
Author(s): Oihane Erice, Maite Merino-Azpitarte, Ander Arbelaiz, Maria Gutierrez-Larranaga, Raul Jimenez-Aguero, Maria J. Perugorria, Luis Bujanda and Jesus M. Banales*
Affiliation:
- Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute - Donostia University Hospital, Paseo del Dr. Begiristain s/n, E-20014, San Sebastian,Spain
Keywords: Biliary epithelium, cholangiocarcinoma, cancer, pathogenesis, stroma, molecular mechanisms, therapy.
Abstract: Cholangiocarcinoma (CCA) is a heterogeneous group of dysplastic disorders affecting the biliary epithelium. It is the second most common primary liver tumor which accounts for around 3% of all gastrointestinal cancers. CCA is very deadly due to its aggressiveness, late diagnosis and high chemoresistance. The incidence is increasing worldwide and the therapeutic options are very limited. Radiotherapy, chemotherapy, surgery and/or liver transplantation may be indicated in patients who meet certain criteria, but chances of success are low. There is therefore increasing interest in understanding the molecular mechanisms involved in the pathogenesis of this cancer type and in identifying new targets for therapy. Current strategies are based on targeting key signaling pathways involved in proliferation, survival, apoptosis and migration. In this review, the most relevant molecular mechanisms involved in the pathogenesis of CCA are discussed and the main preclinical and clinical studies are highlighted. Moreover, future directions in basic and clinical research are indicated.
Export Options
About this article
Cite this article as:
Erice Oihane, Merino-Azpitarte Maite, Arbelaiz Ander, Gutierrez-Larranaga Maria, Jimenez-Aguero Raul, Perugorria J. Maria, Bujanda Luis and Banales M. Jesus*, Molecular Mechanisms of Cholangiocarcinogenesis: New Potential Targets for Therapy, Current Drug Targets 2017; 18 (8) . https://dx.doi.org/10.2174/1389450116666150825113035
DOI https://dx.doi.org/10.2174/1389450116666150825113035 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Roles of UDP-Glucuronosyltransferases in Phytochemical Metabolism of Herbal Medicines and the Associated Herb-Drug Interactions
Current Drug Metabolism Cytotoxicity and Apoptosis Induced by a Plumbagin Derivative in Estrogen Positive MCF-7 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Control of Tumor Markers Using Nanotechnology
Mini-Reviews in Medicinal Chemistry Advances in Hyaluronic Acid-Based Drug Delivery Systems
Current Drug Targets Smart Electrospun Nanofibers for Controlled Drug Release: Recent Advances and New Perspectives
Current Pharmaceutical Design Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma
Current Radiopharmaceuticals Tankyrases: Structure, Function and Therapeutic Implications in Cancer
Current Pharmaceutical Design Pharmacokinetic and Pharmacodynamic Variability: A Daunting Challenge in Drug Therapy
Current Drug Metabolism Nanosuspensions of Poorly Water Soluble Drugs Prepared by Top-down Technologies
Current Pharmaceutical Design Immune Mechanism, Aging, Season and Diseases: Modulatory Role of Melatonin
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Death by Insulin: Management of Self-Harm and Suicide in Diabetes Management
Current Diabetes Reviews Cancer Chemoprevention by Targeting the Epigenome
Current Drug Targets Editorial [Hot topic:Food Addiction & Obesity Treatment Development (Executive Guest Editors: Mark S. Gold and Noni A. Graham)]
Current Pharmaceutical Design Targeting Cell Death in Tumors by Activating Caspases
Current Cancer Drug Targets Docking Studies for Multi-Target Drugs
Current Drug Targets Tolfenamic Acid Interrupts the De Novo Synthesis of the β-Amyloid Precursor Protein and Lowers Amyloid Beta Via a Transcriptional Pathway
Current Alzheimer Research Pathogenesis, Experimental Models and Contemporary Pharmacotherapy of Irritable Bowel Syndrome: Story About the Brain-Gut Axis
Current Neuropharmacology Targeting Bacterial Secretion Systems: Benefits of Disarmament in the Microcosm
Infectious Disorders - Drug Targets Gut Permeability and Microbiota in Parkinson’s Disease: Role of Depression, Tryptophan Catabolites, Oxidative and Nitrosative Stress and Melatonergic Pathways
Current Pharmaceutical Design Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System
Current Cancer Drug Targets